Comments for BIIB - Stockpickr! Your Source for Stock Ideas

Comments for BIIB

Added By	Comments	Type	Date Added
barrons3	Pete Najarian has spotted unusual options action in Biogen (BIIB). High volumes of November 55 call buying suggests this stock could make a sharp move higher, says Najarian. The activity could stem from speculation that this firm could be a takeover target, he adds.	Love	September 29, 2009
barrons3	Icahn hopes a buyout is the future if "we can get a good enough price." He believes that big pharma is going to take over these "large molecule" companies and that the only obstacle holding them back is the ego of the biotech companies. Icahn declined to mention a price for Biogen, except to say it should be a large premium over where it is selling today.	Love	April 15, 2009
barrons3	Look at the money flowing into Celgene (CELG) or into Abbott (ABT) and into Amgen (AMGN) and Biogen (BIIB).	Love	March 12, 2009
barrons3	Carl Icahn is nominating four directors to the board and proposing shareholder resolutions to change the company's state of incorporation from Delaware to North Dakota, the most pro-shareholder jurisdiction in the country, and to limit the size of the board to 13 members.	Love	February 14, 2009
barrons3	And he adds “BiogenIdec [BIIB] is the polar opposite trade. I think this stock is cheap. I’d buy the stock and buy a put.”	Love	January 07, 2009
barrons3	Takeover targets are wide ranging and include Biogen [BIIB], Amylin (AMLN), OSI Pharma [OSIP], and Vertex Pharma [VRTX], says Huckman.	Love	January 07, 2009
Trading Nymph	8	Love	December 30, 2008
barrons3	Icahn's recent winners include Time Warner (TWX); ImClone, which Eli Lilly (LLY) bought recently; and the Stratosphere, a Las Vegas hotel and casino that Icahn sold at a big premium. His effort to get board representation on Biogen (BIIB) came up short, however. And the jury is still out on Yahoo! (YHOO) and Motorola (MOT), in which he has large stakes and board representation.	Love	November 29, 2008
barrons2	Investment funds controlled by investor Carl Icahn raised their stake to 17.5 million shares (6.03%) from the 12.4 million (4.24%) reported on March 31. Icahn, who lost a proxy fight with Biogen, says that he may seek to continue discussions with the company.	Love	August 16, 2008
barrons2	I’m sniffing around Biogen (BIIB), says Karen Finerman. I think it was too beaten down.	Love	August 06, 2008
barrons2	As of March 31st the following were Carl Icahn’s top 5 holdings; Biogen (BIIB), Blockbuster (BBI), Imclone (IMCL), Motorola (MOT) and Yahoo! (YHOO). This hasn’t been the best Carl year, observes Karen Finerman. Sometimes the most talented doctors have patients who die, adds Jeff Macke.	Love	July 30, 2008
barrons2	Don't forget that the whole group is running, including Biogen (BIIB), as the B section of the Journal shows, and Cephalon (CEPH), which seems like nothing but net lately.	Love	July 24, 2008
barrons2	As well as Biogen (BIIB) and Elan (ELN).	Love	May 29, 2008
richard l corley	on a uptrend	Love	May 18, 2008
barrons2	Same with Gilead (GILD) which works well. Celgene (CELG) seems out of steam; Biogen (BIIB) needs a takeover.	Love	April 03, 2008
carmen38	new drugs	Love	February 16, 2008
Stepford	Tysabri will replace Rituxan.	Love	January 19, 2008
badkins729650	poor growth	Hate	December 17, 2007
ladykat	bio-gene technology is coming into its own--it will be invaluable in the future	Love	November 25, 2007
deleteme	Don't own right now; a sure thing as far as biotech goes with strategic options	Love	November 13, 2007
tejakota	All forgot that this is for sale - and it could be sold any day. At what price - we dont know. But at 73 its down 20% from 85 it hit 10days back on buyout news. Has to go back there.	Love	November 02, 2007
sharanonline	takeover target	Love	October 27, 2007
xcountrydist	Bought this one at $47. Will probably sell soon now that it's popped after announcing it's for sale.	Love	October 13, 2007
supratrade	BUY	Love	August 25, 2007
michaelwil	Up 20%, anymore upside to this drug company?	Love	July 27, 2007
stockerblog	Former holdings over $250,000	Love	June 17, 2007
sarah z	Biogen Idec recently announced a $3 billion dollar buyback. Biogen Idec Inc. said this past Sunday (6-3-07) a trial showed the drug maker's Zevalin treatment helped more patients with lymphoma improve their condition than standard treatments. Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, and immunology in the United States and internationally. The stock trades for 13x cash flow.	Love	June 06, 2007
richstockpickr	strong biotech	Love	June 04, 2007
shgadeliq	I have some	Love	June 01, 2007
stockerblog	9.1 million short	Love	May 26, 2007